Our top pick for
Cleveland BioLabs Inc is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 18 staff and has a trailing 12-month revenue of around $106,900.
|52-week range||$2.11 - $4.04|
|50-day moving average||$3.62|
|200-day moving average||$3.62|
|Wall St. target price||$2.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.74|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-24)||N/A|
|1 month (2022-09-01)||N/A|
|3 months (2022-07-01)||N/A|
|6 months (2022-04-01)||N/A|
|1 year (2021-10-05)||-100.00%|
|2 years (2020-10-05)||-100.00%|
|3 years (2019-10-04)||-100.00%|
|5 years (2017-10-05)||-100.00%|
|Gross profit TTM||$-428,128|
|Return on assets TTM||-20.33%|
|Return on equity TTM||-31.86%|
|Market capitalisation||$49.1 million|
TTM: trailing 12 months
We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.
Cleveland BioLabs's shares were split on a 1:20 basis on 27 January 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.
Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $2.11 up to $4.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.6837. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).
Cytocom, Inc. , a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.